AnalystsEun YangEun Yang's Stock Forecasts
AnalystsEun Yang
Analyst Ranking
Bottom 2%
#4488 out of 4554 analysts
Average Return
-16.76%
Win Rate
33%10 out of 30
Risk vs Reward
Poor
Good
Eun Yang's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Talphera IncTLPH | +97.52% | $105.00 | $207.40 | 2013-04-07 - 2014-04-08 | Strong Buy |
La Jolla Pharmaceutical CoLJPC | +74.41% | $24.47 | $6.26 | 2018-08-08 - 2019-01-14 | Sell |
United Therapeutics CorpUTHR | +58.90% | $100.49 | $159.68 | 2020-03-09 - 2021-03-10 | Strong Buy |
Lumos Pharma IncLUMO | +44.72% | $8.34 | $12.07 | 2020-04-15 - 2021-04-16 | Strong Buy |
Aerovate Therapeutics IncAVTE | +37.83% | $13.80 | $19.02 | 2021-07-25 - 2022-07-25 | Strong Buy |
Eun Yang Analyst Color
Get additional color on Eun Yang's coverage of popular stocks
Eun Yang's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Aerovate Therapeutics IncAVTE | 2 | Strong Buy | $65.00 | +200.93% | Assumes | 25 days ago |
Astria Therapeutics IncATXS | 2 | Strong Buy | $27.00 | +156.17% | Maintains | 25 days ago |
Rallybio CorpRLYB | 2 | Hold | $1.50 | -10.18% | Downgrades | 2 months ago |
Reneo Pharmaceuticals IncRPHM | 2 | Hold | $1.80 | +2.27% | Downgrades | 4 months ago |
Bridgebio Pharma IncBBIO | 1 | Hold | $33.00 | +32.26% | Downgrades | 9 months ago |
Biomea Fusion IncBMEA | 2 | Hold | $28.00 | +150.90% | Downgrades | 10 months ago |
Enliven Therapeutics IncELVN | 1 | Strong Buy | $27.00 | N/A | Initiates Coverage On | a year ago |
Genasys IncGNSS | 1 | Buy | $7.00 | N/A | Maintains | a year ago |
Taysha Gene Therapies IncTSHA | 1 | Hold | $1.50 | N/A | Downgrades | a year ago |
Albireo Pharma IncALBO | 2 | Hold | $42.00 | N/A | Downgrades | a year ago |
Lumos Pharma IncLUMO | 3 | Hold | $7.00 | N/A | Downgrades | a year ago |
Prime Medicine IncPRME | 1 | Strong Buy | $25.00 | N/A | Initiates Coverage On | a year ago |
Nucana PLCNCNA | 1 | Strong Buy | $75.00 | N/A | Maintains | 2 years ago |
Blueprint Medicines CorpBPMC | 3 | Strong Buy | $84.00 | N/A | Maintains | 2 years ago |
United Therapeutics CorpUTHR | 3 | Strong Buy | $245.00 | N/A | Maintains | 2 years ago |
Pyxis Oncology IncPYXS | 1 | Strong Buy | $25.00 | N/A | Initiates Coverage On | 2 years ago |
Verve Therapeutics IncVERV | 1 | Strong Buy | N/A | N/A | Initiates Coverage On | 3 years ago |
Centessa Pharmaceuticals PLCCNTA | 1 | Strong Buy | $35.00 | N/A | Initiates Coverage On | 3 years ago |
Five Prime Therapeutics IncFPRX | 1 | Hold | $38.00 | N/A | Downgrades | 3 years ago |
Curevac NvCVAC | 1 | Hold | $58.00 | N/A | Initiates Coverage On | 4 years ago |
La Jolla Pharmaceutical CoLJPC | 2 | Hold | $6.00 | N/A | Upgrades | 5 years ago |
Talphera IncTLPH | 6 | Strong Buy | $160.00 | N/A | Upgrades | 6 years ago |
Amgen IncAMGN | 2 | Strong Buy | $220.00 | N/A | Maintains | 6 years ago |
Bioverativ IncBIVV | 1 | Hold | N/A | N/A | Downgrades | 6 years ago |
Radius Health IncRDUS1 | 1 | Hold | $31.00 | N/A | Maintains | 6 years ago |
Dova Pharmaceuticals IncDOVA | 1 | Strong Buy | $30.00 | N/A | Initiates Coverage On | 7 years ago |
Aileron Therapeutics IncALRN | 1 | Strong Buy | $400.00 | N/A | Initiates Coverage On | 7 years ago |
Biogen IncBIIB | 1 | Hold | $310.00 | N/A | Assumes | 7 years ago |
Gilead Sciences IncGILD | 1 | Hold | $80.00 | N/A | Assumes | 7 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.